Clinical trials: Hematopoietic Malignancy
Acute Myeloid Leukemia, Essential Thrombocythemia
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors).
- Conditions
- Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04282187
- Testing
- Decitabine, Ruxolitinib, Fedratinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Trial name
- NCT04742595
- Testing
- SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003064
- Testing
- filgrastim, carboplatin, etoposide phosphate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors
This clinical trial compares the impact of four types of meditation practices, breathing only, focused attention only, mindfulness only, and breathing, focused attention and mindfulness combined, for relaxation in cancer…
- Trial name
- NCT06500377
- Testing
- Biospecimen Collection, Meditation Therapy, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Thrombosis, Venous, Bleeding Hemorrhage
Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer, after disease progression. VTE is increasingly recognized as a complication in patients with hematologic malignancies and various studies…
- Conditions
- Thrombosis, Venous, Bleeding Hemorrhage, Venous Thromboembolic Disease, Hematologic Malignancy
- Trial name
- NCT05396157
- Where
- Canada
- Volunteers
- 813 people
- Sponsor
- Mount Sinai Hospital, Canada
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors
This clinical trial tests how well a virtual mindfulness and weight management program to mitigate risk of relapse and improve well being for obese cancer survivors in community practice and rural areas.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Obesity-Related Malignant Neoplasm
- Trial name
- NCT06030427
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Health Promotion and Education
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Unrecognized Condition: Mature B or T-cell Neoplasm
Cyclosporine Plus Methotrexate or Alemtuzumab
The primary aim of the study was to compare the efficacy of the procedure in terms of event-free survival between patients receiving cyclosporine (CsA) plus either alemtuzumab (CAMPATH-1H ) or methotrexate (MTX) after matched…
- Trial name
- NCT02701517
- Testing
- Cyclosporine + METHOTREXATE, Cyclosporine + CAMPATH-1H
- Where
- 5 sites in Poland, Spain
- Volunteers
- 72 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04432506
- Testing
- Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Anxiety, Depression
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started…
- Conditions
- Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT07336238
- Testing
- Psychotherapy, Psilocybin, Survey Administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Washington
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Contrast-enhanced abdominal CT will be performed 1-2 weeks after allogeneic stem cell transplant, and radiographic evidence of mucosal inflammation will be correlated with the subsequent development of acute graft versus host…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Multiple Myeloma
- Trial name
- GVHD (NCT02117115)
- Testing
- Dynamic contrast-enhanced computed tomography, Ioversol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Elderly patients with acute myeloid leukemia (AML) often face unfavorable prognostic factors such as multiple comorbidities, adverse cytogenetic profiles, and pre-existing hematological disorders.
- Trial name
- NCT06571825
- Testing
- Venetoclax, Allogeneic transplant
- Where
- China
- Volunteers
- 118 people
- Sponsor
- He Huang
Acute Lymphoblastic Leukemia
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
Pharmacogenomics (PG) offers the opportunity to individualize treatment according to patient genetic variations which influence activity of enzyme metabolizing or acting in the pathway of prescribed chemotherapy drugs.
- Trial name
- NCT02670564
- Testing
- Pharmacogenomics, Busulfan plasma level measurements
- Where
- 4 sites in Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Swiss Pediatric Oncology Group
Extranodal NK-T-Cell Lymphoma, Nasal Type
MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of methotrexate, etoposide, pegaspargase and dexamethasone (MEDA) chemotherapy and autologous hematopoietic stem cell transplantation (Auto-HSCT) in patients with…
- Trial name
- NCT02764281
- Testing
- MEDA, Auto-HSCT
- Where
- 7 sites in China
- Volunteers
- 53 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Leukemia, Lymphoma
Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.
Patients with hematologic malignancies requiring intensive chemotherapy are at risk for life-threatening complications. Organ failure may appear rapidly and delay in initiating life-sustaining interventions may result in…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- ALHERT (NCT06409767)
- Testing
- Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.
- Where
- 10 sites in France
- Volunteers
- 2,224 people
- Sponsor
- University Hospital, Angers
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Development of the Oncology Opportunity Cost Assessment Tool
This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients.
- Trial name
- NCT04694911
- Testing
- Focus Group, Interview, Research or Clinical Assessment Tool
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Jefferson University
Cancer, Bone Marrow Neoplasms
The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation
Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology…
- Conditions
- Cancer, Bone Marrow Neoplasms, Anxiety, Depression
- Trial name
- NCT03640325
- Testing
- PRISM (Promoting Resilience in Stress Management)
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Seattle Children's Hospital
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
- Trial name
- NCT06640010
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation
The protocol treatment is to evaluate clinical effects of donor-derived natural killer cells that are given after HLA-mismatched hematopoietic cell transplantation.
- Trial name
- DNKI-II (NCT01795378)
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Asan Medical Center
GVHD, Hematopoietic Cell Transplantation (HCT)
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes
- Trial name
- NCT07302776
- Testing
- Tacrolimus, Early Tacrolimus Taper Strategy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.